KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Return on Capital Employed (2018 - 2026)

Amneal Pharmaceuticals has reported Return on Capital Employed over the past 8 years, most recently at 14.29% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 369.0% year-over-year to 14.29%; the TTM value through Dec 2025 reached 14.29%, up 369.0%, while the annual FY2025 figure was 14.55%, 397.0% up from the prior year.
  • Return on Capital Employed for Q4 2025 was 14.29% at Amneal Pharmaceuticals, up from 13.51% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 16.46% in Q2 2025 and troughed at 4.56% in Q2 2022.
  • A 5-year average of 6.64% and a median of 6.71% in 2024 define the central range for Return on Capital Employed.
  • Biggest five-year swings in Return on Capital Employed: crashed -867bps in 2022 and later skyrocketed 1500bps in 2023.
  • Year by year, Return on Capital Employed stood at 4.66% in 2021, then crashed by -95bps to 0.23% in 2022, then surged by 3148bps to 7.48% in 2023, then surged by 42bps to 10.6% in 2024, then surged by 35bps to 14.29% in 2025.
  • Business Quant data shows Return on Capital Employed for AMRX at 14.29% in Q4 2025, 13.51% in Q3 2025, and 16.46% in Q2 2025.